Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Recapitulating the human segmentation clock with pluripotent stem cells.

Matsuda M, Yamanaka Y, Uemura M, Osawa M, Saito MK, Nagahashi A, Nishio M, Guo L, Ikegawa S, Sakurai S, Kihara S, Maurissen TL, Nakamura M, Matsumoto T, Yoshitomi H, Ikeya M, Kawakami N, Yamamoto T, Woltjen K, Ebisuya M, Toguchida J, Alev C.

Nature. 2020 Apr;580(7801):124-129. doi: 10.1038/s41586-020-2144-9. Epub 2020 Apr 1.

PMID:
32238941
2.

Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas.

Komura S, Ito K, Ohta S, Ukai T, Kabata M, Itakura F, Semi K, Matsuda Y, Hashimoto K, Shibata H, Sone M, Jo N, Sekiguchi K, Ohno T, Akiyama H, Shimizu K, Woltjen K, Ozawa M, Toguchida J, Yamamoto T, Yamada Y.

Nat Commun. 2019 Sep 5;10(1):3999. doi: 10.1038/s41467-019-11745-1.

3.

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Nishida Y, Kawai A, Toguchida J, Ogose A, Ae K, Kunisada T, Matsumoto Y, Matsunobu T, Takahashi K, Nishida K, Ozaki T.

Int J Clin Oncol. 2019 Nov;24(11):1498-1505. doi: 10.1007/s10147-019-01512-z. Epub 2019 Jul 22.

PMID:
31332613
4.

In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes.

Kawai S, Yoshitomi H, Sunaga J, Alev C, Nagata S, Nishio M, Hada M, Koyama Y, Uemura M, Sekiguchi K, Maekawa H, Ikeya M, Tamaki S, Jin Y, Harada Y, Fukiage K, Adachi T, Matsuda S, Toguchida J.

Nat Biomed Eng. 2019 Jul;3(7):558-570. doi: 10.1038/s41551-019-0410-7. Epub 2019 Jun 10.

PMID:
31182836
5.

Bi-allelic loss of function variants of TBX6 causes a spectrum of malformation of spine and rib including congenital scoliosis and spondylocostal dysostosis.

Otomo N, Takeda K, Kawai S, Kou I, Guo L, Osawa M, Alev C, Kawakami N, Miyake N, Matsumoto N, Yasuhiko Y, Kotani T, Suzuki T, Uno K, Sudo H, Inami S, Taneichi H, Shigematsu H, Watanabe K, Yonezawa I, Sugawara R, Taniguchi Y, Minami S, Kaneko K, Nakamura M, Matsumoto M, Toguchida J, Watanabe K, Ikegawa S.

J Med Genet. 2019 Sep;56(9):622-628. doi: 10.1136/jmedgenet-2018-105920. Epub 2019 Apr 22.

PMID:
31015262
6.

An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.

Hino K, Zhao C, Horigome K, Nishio M, Okanishi Y, Nagata S, Komura S, Yamada Y, Toguchida J, Ohta A, Ikeya M.

Stem Cell Reports. 2018 Nov 13;11(5):1106-1119. doi: 10.1016/j.stemcr.2018.10.007. Epub 2018 Nov 1.

7.

Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments.

Yoshitomi H, Kobayashi S, Miyagawa-Hayashino A, Okahata A, Doi K, Nishitani K, Murata K, Ito H, Tsuruyama T, Haga H, Matsuda S, Toguchida J.

Nat Commun. 2018 Sep 19;9(1):3762. doi: 10.1038/s41467-018-06187-0.

8.

Modeling human somite development and fibrodysplasia ossificans progressiva with induced pluripotent stem cells.

Nakajima T, Shibata M, Nishio M, Nagata S, Alev C, Sakurai H, Toguchida J, Ikeya M.

Development. 2018 Aug 23;145(16). pii: dev165431. doi: 10.1242/dev.165431.

9.

Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304.

Tanaka K, Ogawa G, Mizusawa J, Naka N, Kawai A, Takahashi M, Hiruma T, Matsumoto Y, Tsuchiya H, Nakayama R, Hatano H, Emori M, Hosaka M, Yoshida Y, Toguchida J, Abe S, Asanuma K, Yokoyama R, Hiraga H, Yonemoto T, Morii T, Matsumoto S, Nagano A, Yoshikawa H, Fukuda H, Ozaki T, Iwamoto Y.

World J Surg Oncol. 2018 Aug 10;16(1):162. doi: 10.1186/s12957-018-1462-y.

10.

Current state of therapeutic development for rare cancers in Japan, and proposals for improvement.

Kawai A, Goto T, Shibata T, Tani K, Mizutani S, Nishikawa A, Shibata T, Matsumoto S, Nagata K, Narukawa M, Matsui S, Ando M, Toguchida J, Monden M, Heike T, Kimura S, Ueda R.

Cancer Sci. 2018 May;109(5):1731-1737. doi: 10.1111/cas.13568.

11.

Longitudinal study of the activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva.

Nakahara Y, Kitoh H, Nakashima Y, Toguchida J, Haga N.

Disabil Rehabil. 2019 Mar;41(6):699-704. doi: 10.1080/09638288.2017.1405083. Epub 2017 Nov 16.

PMID:
29145736
12.

Chondroblastoma of extra-craniofacial bones: Clinicopathological analyses of 103 cases.

Konishi E, Nakashima Y, Mano M, Tomita Y, Kubo T, Araki N, Morii E, Yoshikawa H, Haga H, Toguchida J, Ueda T, Osawa M, Hoshi M, Inoue T, Aono M, Yanagisawa A.

Pathol Int. 2017 Oct;67(10):495-502. doi: 10.1111/pin.12586.

PMID:
28971570
13.

Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Hino K, Horigome K, Nishio M, Komura S, Nagata S, Zhao C, Jin Y, Kawakami K, Yamada Y, Ohta A, Toguchida J, Ikeya M.

J Clin Invest. 2017 Sep 1;127(9):3339-3352. doi: 10.1172/JCI93521. Epub 2017 Jul 31.

14.

Analysis of neural crest cells from Charcot-Marie-Tooth disease patients demonstrates disease-relevant molecular signature.

Kitani-Morii F, Imamura K, Kondo T, Ohara R, Enami T, Shibukawa R, Yamamoto T, Sekiguchi K, Toguchida J, Mizuno T, Nakagawa M, Inoue H.

Neuroreport. 2017 Sep 6;28(13):814-821. doi: 10.1097/WNR.0000000000000831.

PMID:
28704293
15.

A clinical trial for Kienböck disease by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts: A report of five cases.

Ikeguchi R, Aoyama T, Kakinoki R, Ueda M, Kasai Y, Maekawa T, Tada H, Yamamoto M, Matsuda S, Nakamura T, Toguchida J.

J Orthop Sci. 2019 Jul;24(4):750-756. doi: 10.1016/j.jos.2017.02.002. Epub 2017 Mar 6. No abstract available.

PMID:
28274511
16.

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.

Tanaka K, Joyama S, Chuman H, Hiraga H, Morioka H, Yoshikawa H, Hosaka M, Takahashi M, Kubo T, Hatano H, Kaya M, Toguchida J, Nishida Y, Nagano A, Tsumura H, Iwamoto Y.

World J Surg Oncol. 2016 Dec 8;14(1):306.

17.

Recipient bone marrow-derived stromal cells prolong graft survival in a rat hind limb allotransplantation model.

Ikeguchi R, Kakinoki R, Ohta S, Oda H, Yurie H, Kaizawa Y, Mitsui H, Aoyama T, Toguchida J, Matsuda S.

Microsurgery. 2017 Sep;37(6):632-640. doi: 10.1002/micr.30128. Epub 2016 Nov 17.

PMID:
27859595
18.

BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence.

Hayashi Y, Hsiao EC, Sami S, Lancero M, Schlieve CR, Nguyen T, Yano K, Nagahashi A, Ikeya M, Matsumoto Y, Nishimura K, Fukuda A, Hisatake K, Tomoda K, Asaka I, Toguchida J, Conklin BR, Yamanaka S.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13057-13062. Epub 2016 Oct 28.

19.

[Application of disease-specific iPS cells for intractable diseases-from pathomechanisms to drug discovery].

Toguchida J, Hino K, Ikeya M.

Clin Calcium. 2016 Apr;26(4):593-600. doi: CliCa1604593600. Japanese.

PMID:
27013631
20.

Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, Toguchida J.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15438-43. doi: 10.1073/pnas.1510540112. Epub 2015 Nov 30.

21.

SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.

Tamaki S, Fukuta M, Sekiguchi K, Jin Y, Nagata S, Hayakawa K, Hineno S, Okamoto T, Watanabe M, Woltjen K, Ikeya M, Kato T Jr, Toguchida J.

PLoS One. 2015 Nov 16;10(11):e0142991. doi: 10.1371/journal.pone.0142991. eCollection 2015.

22.

Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.

Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, Woltjen K, Kobayashi Y, Nagata S, Ikeya M, Kato T Jr, Okamoto T, Matsuda S, Toguchida J.

PLoS One. 2015 Jul 10;10(7):e0131998. doi: 10.1371/journal.pone.0131998. eCollection 2015.

23.

Primary central chondrosarcoma of long bone, limb girdle and trunk: Analysis of 174 cases by numerical scoring on histology.

Konishi E, Nakashima Y, Mano M, Tomita Y, Nagasaki I, Kubo T, Araki N, Haga H, Toguchida J, Ueda T, Sakuma T, Imahori M, Morii E, Yoshikawa H, Tsukamoto Y, Futani H, Wakasa K, Hoshi M, Hamada S, Takeshita H, Inoue T, Aono M, Kawabata K, Murata H, Katsura K, Urata Y, Ueda H, Yanagisawa A.

Pathol Int. 2015 Sep;65(9):468-75. doi: 10.1111/pin.12324. Epub 2015 Jul 1.

24.

Screening of BCOR-CCNB3 sarcoma using immunohistochemistry for CCNB3: A clinicopathological report of three pediatric cases.

Shibayama T, Okamoto T, Nakashima Y, Kato T, Sakurai T, Minamiguchi S, Kataoka TR, Shibuya S, Yoshizawa A, Toguchida J, Haga H.

Pathol Int. 2015 Aug;65(8):410-4. doi: 10.1111/pin.12319. Epub 2015 Jun 3.

PMID:
26037154
25.

Clinical trial for idiopathic osteonecrosis of femoral head by multipotent mesenchynal stromal cells.

Aoyama T, Toguchida J.

Nihon Rinsho. 2015 Jun;73 Suppl 5:468-72. Japanese. No abstract available.

PMID:
30458099
26.

Application of patients - derived iPS cells for intractable musculoskeletal diseases.

Toguchida J, Yokoyama K, Ikeya M, Heike T.

Nihon Rinsho. 2015 Jun;73 Suppl 5:416-22. Japanese. No abstract available.

PMID:
30458090
27.

New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva.

Matsumoto Y, Ikeya M, Hino K, Horigome K, Fukuta M, Watanabe M, Nagata S, Yamamoto T, Otsuka T, Toguchida J.

Stem Cells. 2015 Jun;33(6):1730-42. doi: 10.1002/stem.1981.

28.

Phenotypic differences of patients with fibrodysplasia ossificans progressive due to p.Arg258Ser variants of ACVR1.

Nakahara Y, Suzuki R, Katagiri T, Toguchida J, Haga N.

Hum Genome Var. 2015 Dec 10;2:15055. doi: 10.1038/hgv.2015.55. eCollection 2015.

29.

IKKβ in postnatal perichondrium remotely controls endochondral ossification of the growth plate through downregulation of MCP-5.

Kobayashi K, Toguchida J, Karin M, Kato T Jr.

Cell Death Differ. 2015 May;22(5):852-61. doi: 10.1038/cdd.2014.192. Epub 2014 Dec 19.

30.

Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media.

Fukuta M, Nakai Y, Kirino K, Nakagawa M, Sekiguchi K, Nagata S, Matsumoto Y, Yamamoto T, Umeda K, Heike T, Okumura N, Koizumi N, Sato T, Nakahata T, Saito M, Otsuka T, Kinoshita S, Ueno M, Ikeya M, Toguchida J.

PLoS One. 2014 Dec 2;9(12):e112291. doi: 10.1371/journal.pone.0112291. eCollection 2014.

31.

Rehabilitation program after mesenchymal stromal cell transplantation augmented by vascularized bone grafts for idiopathic osteonecrosis of the femoral head: a preliminary study.

Aoyama T, Fujita Y, Madoba K, Nankaku M, Yamada M, Tomita M, Goto K, Ikeguchi R, Kakinoki R, Matsuda S, Nakamura T, Toguchida J.

Arch Phys Med Rehabil. 2015 Mar;96(3):532-9. doi: 10.1016/j.apmr.2014.09.040. Epub 2014 Oct 31.

32.

Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway.

Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S, Nasu A, Matsumoto Y, Izawa K, Horigome K, Kusaka T, Tanaka T, Saito MK, Yasumi T, Nishikomori R, Ohara O, Nakayama N, Nakahata T, Heike T, Toguchida J.

Arthritis Rheumatol. 2015 Jan;67(1):302-14. doi: 10.1002/art.38912.

33.

IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress.

Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, Kamel W, Ueki A, Ishikawa T, Chiyoda T, Osuka S, Onishi N, Ikeda H, Kamei J, Matsuo K, Fukuchi Y, Nagai T, Toguchida J, Toyama Y, Muto A, Saya H.

Cancer Res. 2014 Nov 15;74(22):6531-41. doi: 10.1158/0008-5472.CAN-14-0914. Epub 2014 Oct 1.

34.

The effect of walking speed on gait kinematics and kinetics after endoprosthetic knee replacement following bone tumor resection.

Okita Y, Tatematsu N, Nagai K, Nakayama T, Nakamata T, Okamoto T, Toguchida J, Ichihashi N, Matsuda S, Tsuboyama T.

Gait Posture. 2014 Sep;40(4):622-7. doi: 10.1016/j.gaitpost.2014.07.012. Epub 2014 Jul 22.

PMID:
25103777
35.

Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.

Totoki Y, Yoshida A, Hosoda F, Nakamura H, Hama N, Ogura K, Yoshida A, Fujiwara T, Arai Y, Toguchida J, Tsuda H, Miyano S, Kawai A, Shibata T.

Genome Res. 2014 Sep;24(9):1411-20. doi: 10.1101/gr.160598.113. Epub 2014 Jul 14.

36.

AFAP1L1, a novel associating partner with vinculin, modulates cellular morphology and motility, and promotes the progression of colorectal cancers.

Takahashi R, Nagayama S, Furu M, Kajita Y, Jin Y, Kato T, Imoto S, Sakai Y, Toguchida J.

Cancer Med. 2014 Aug;3(4):759-74. doi: 10.1002/cam4.237. Epub 2014 Apr 10.

37.

[Bone and Stem Cells. Advancement of regenerative medicine in the locomotive system using iPS cells].

Toguchida J.

Clin Calcium. 2014 Apr;24(4):587-92. doi: CliCa1404587592. Review. Japanese.

PMID:
24681505
38.

Good response to chemotherapy spares irradiation for extrarenal rhabdoid tumor conferring better activities of daily living.

Asada N, Kato I, Daifu T, Umeda K, Hiramatsu H, Okamoto T, Toguchida J, Yamawaki S, Yoshikawa K, Adachi S, Heike T, Watanabe K.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e57-9. doi: 10.1097/MPH.0000000000000150.

PMID:
24663072
39.

An exploratory clinical trial for idiopathic osteonecrosis of femoral head by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts.

Aoyama T, Goto K, Kakinoki R, Ikeguchi R, Ueda M, Kasai Y, Maekawa T, Tada H, Teramukai S, Nakamura T, Toguchida J.

Tissue Eng Part B Rev. 2014 Aug;20(4):233-42. doi: 10.1089/ten.TEB.2014.0090. Epub 2014 Apr 9.

40.

Current status of multipotent mesenchymal stromal cells.

Husain SR, Ohya Y, Toguchida J, Puri RK.

Tissue Eng Part B Rev. 2014 Jun;20(3):189. doi: 10.1089/ten.TEB.2014.0105. Epub 2014 Mar 31. No abstract available.

41.

Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation.

Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, Sami S, Baba S, Barruet E, Nasu A, Asaka I, Otsuka T, Yamanaka S, Conklin BR, Toguchida J, Hsiao EC.

Orphanet J Rare Dis. 2013 Dec 9;8:190. doi: 10.1186/1750-1172-8-190.

42.

Compensation by nonoperated joints in the lower limbs during walking after endoprosthetic knee replacement following bone tumor resection.

Okita Y, Tatematsu N, Nagai K, Nakayama T, Nakamata T, Okamoto T, Toguchida J, Matsuda S, Ichihashi N, Tsuboyama T.

Clin Biomech (Bristol, Avon). 2013 Oct;28(8):898-903. doi: 10.1016/j.clinbiomech.2013.08.005. Epub 2013 Aug 24.

PMID:
24008057
43.

Characteristics of flexed knee gait and functional outcome of a patient who underwent knee reconstruction with a hingeless prosthesis for bone tumor resection: a case report with gait analysis and comparison with healthy subjects.

Okita Y, Tatematsu N, Nagai K, Nakayama T, Nakamata T, Okamoto T, Toguchida J, Ichihashi N, Tsuboyama T.

Eur J Phys Rehabil Med. 2013 Jul 9. [Epub ahead of print]

44.

Characteristics of flexed knee gait and functional outcome of a patient who underwent knee reconstruction with a hingeless prosthesis for bone tumor resection: a case report with gait analysis and comparison with healthy subjects.

Okita Y, Tatematsu N, Nagai K, Nakayama T, Nakamata T, Okamoto T, Toguchida J, Ichihashi N, Tsuboyama T.

Eur J Phys Rehabil Med. 2013 Dec;49(6):849-55. Epub 2013 Jul 2.

45.

Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin.

Nasu A, Ikeya M, Yamamoto T, Watanabe A, Jin Y, Matsumoto Y, Hayakawa K, Amano N, Sato S, Osafune K, Aoyama T, Nakamura T, Kato T, Toguchida J.

PLoS One. 2013;8(1):e53771. doi: 10.1371/journal.pone.0053771. Epub 2013 Jan 31.

46.

The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1).

Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J.

PLoS One. 2013;8(1):e49709. doi: 10.1371/journal.pone.0049709. Epub 2013 Jan 9.

47.

Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells.

Hayakawa K, Ikeya M, Fukuta M, Woltjen K, Tamaki S, Takahara N, Kato T Jr, Sato S, Otsuka T, Toguchida J.

Biochem Biophys Res Commun. 2013 Mar 22;432(4):713-9. doi: 10.1016/j.bbrc.2013.01.003. Epub 2013 Jan 10.

PMID:
23313505
48.

EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice.

Yamada K, Ohno T, Aoki H, Semi K, Watanabe A, Moritake H, Shiozawa S, Kunisada T, Kobayashi Y, Toguchida J, Shimizu K, Hara A, Yamada Y.

J Clin Invest. 2013 Feb;123(2):600-10. doi: 10.1172/JCI63572. Epub 2013 Jan 2.

49.

Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells.

Kajiwara M, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S, Yamanaka S.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12538-43. doi: 10.1073/pnas.1209979109. Epub 2012 Jul 16. Erratum in: Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14716.

50.

SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group.

Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, Emori M, Nagoya S, Kaya M, Torigoe T, Ueda E, Takahashi A, Ishii T, Tatezaki S, Toguchida J, Tsuchiya H, Osanai T, Sugita T, Sugiura H, Ieguchi M, Ihara K, Hamada K, Kakizaki H, Morii T, Yasuda T, Tanizawa T, Ogose A, Yabe H, Yamashita T, Sato N, Wada T.

Cancer Sci. 2012 Sep;103(9):1625-30. doi: 10.1111/j.1349-7006.2012.02370.x. Epub 2012 Aug 7.

Supplemental Content

Loading ...
Support Center